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Guidelines for the Use of Antiretroviral Agents
in Pediatric HIV Infection
Summary
Although the pathogenesis of human immunodeficiency virus (HIV) infection
and the general virologic and immunologic principles underlying the use of
antiretroviral therapy are similar for all HIV-infected persons, there are unique
considerations needed for HIV-infected infants, children, and adolescents, in-
cluding a) acquisition of infection through perinatal exposure for many infected
children; b) in utero exposure to zidovudine (ZDV) and other antiretroviral medi-
cations in many perinatally infected children; c) differences in diagnostic
evaluation in perinatal infection; d) differences in immunologic markers (e.g.,
CD4+ T-lymphocyte count) in young children; e) changes in pharmacokinetic pa-
rameters with age caused by the continuing development and maturation of
organ systems involved in drug metabolism and clearance; f) differences in the
clinical and virologic manifestations of perinatal HIV infection secondary to the
occurrence of primary infection in growing, immunologically immature persons;
and g) special considerations associated with adherence to treatment for chil-
dren and adolescents. This report addresses the pediatric-specific issues
associated with antiretroviral treatment and provides guidelines to health-care
providers caring for infected infants, children, and adolescents.*
INTRODUCTION
In 1993, the Working Group on Antiretroviral Therapy and Medical Management of
HIV-Infected Children, composed of specialists caring for human immunodeficiency
virus (HIV)-infected infants, children, and adolescents, was convened by the National
Pediatric and Family HIV Resource Center (NPHRC). On the basis of available data and
a consensus reflecting clinical experience, the Working Group concluded that anti-
retroviral therapy was indicated for any child with a definitive diagnosis of HIV
infection who had evidence of substantial immunodeficiency (based on age-related
CD4+ T-lymphocyte count thresholds) and/or who had HIV-associated symptoms.
Zidovudine (ZDV) monotherapy was recommended as the standard of care for initia-
tion of therapy. Routine antiretroviral therapy for infected children who were
asymptomatic or had only minimal symptoms (e.g., isolated lymphadenopathy or
hepatomegaly) and normal immune status was not recommended (1 ).
Since the Working Group developed the 1993 recommendations, dramatic
advances in laboratory and clinical research have been made. The rapidity and mag-
nitude of HIV replication during all stages of infection are greater than previously
believed and account for the emergence of drug-resistant viral variants when
antiretroviral treatment does not maximally suppress replication (2,3 ). New assays
that quantitate plasma HIV RNA copy number have become available, permitting a
*Information included in these guidelines may not represent Food and Drug Administration
(FDA) approval or approved labeling for the particular product or indications in question.
Specifically, the terms “safe” and “effective” may not be synonymous with the FDA-defined
legal standards for product approval.
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sensitive assessment of risk for disease progression and adequacy of antiretroviral
therapy. A new class of antiretroviral drugs, protease inhibitors, has become available;
these agents have reduced HIV viral load to levels that are undetectable and have
reduced disease progression and mortality in many HIV-infected persons. Therefore,
therapeutic strategies now focus on early institution of antiretroviral regimens capa-
ble of maximally suppressing viral replication to reduce the development of resistance
and to preserve immunologic function. Additionally, the results of Pediatric AIDS Clini-
cal Trials Group (PACTG) protocol 076 have demonstrated that the risk for perinatal
HIV transmission can be substantially diminished with the use of a regimen of ZDV
administered during pregnancy, during labor, and to the newborn (4 ).
These advances in HIV research have led to major changes in the treatment and
monitoring of HIV infection in the United States. A summary of the basic principles
underlying therapy of HIV-infected persons has been formulated by the National Insti-
tutes of Health (NIH) Panel to Define Principles of Therapy of HIV Infection (5 ).
Treatment recommendations for infected adults and post-pubertal adolescents have
been developed by the U.S. Department of Health and Human Services Panel of Clini-
cal Practices for Treatment of HIV Infection (5 ). 
Although the pathogenesis of HIV infection and the general virologic and immu-
nologic principles underlying the use of antiretroviral therapy are similar for all
HIV-infected persons, there are unique considerations needed for HIV-infected infants,
children, and adolescents. Most HIV infections in children are acquired perinatally, and
most perinatal transmission occurs during or near the time of birth, which raises the
possibility of initiating treatment in an infected infant during the period of initial (e.g.,
primary) HIV infection (if sensitive diagnostic tests are used to define the infant’s infec-
tion status early in life). Perinatal HIV infection occurs during the development of the
infant’s immune system; thus, both the clinical manifestations of HIV infection and the
course of immunologic and virologic markers of infection differ from those for adults.
Treatment of perinatally infected children will occur in the context of prior exposure to
ZDV and other antiretroviral drugs used during pregnancy and the neonatal period,
either for maternal treatment, to prevent perinatal transmission, or both (6,7 ). Addi-
tionally, drug pharmacokinetics change during the transition from the newborn period
to adulthood, requiring specific evaluation of drug dosing and toxicity in infants and
children. Finally, optimizing adherence to therapy in children and adoles- cents re-
quires specific considerations.
To update the 1993 antiretroviral treatment guidelines for children and to provide
guidelines for antiretroviral treatment similar to those for HIV-infected adults (5 ),
NPHRC, the Health Resources and Services Administration, and NIH reconvened the
Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected
Children, consisting of experts caring for HIV-infected children and adolescents, family
members of HIV-infected children, and government agency representatives. The
Working Group met in June 1996 and again in July 1997 to establish and finalize new
guidelines for the treatment of HIV-infected infants, children, and adolescents.
The treatment recommendations provided in this report are based on published
and unpublished data regarding the treatment of HIV infection in adults and children
and, when no definitive data were available, the clinical experience of the Working
Group members. The Working Group intended the guidelines to be flexible and not
to supplant the clinical judgement of experienced health-care providers. These
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guidelines will need to be modified as new information and clinical experience be-
come available.
BACKGROUND
Concepts Considered in the Formulation
of Pediatric Treatment Guidelines
The following concepts were considered in the formulation of these guidelines:
• Identification of HIV-infected women before or during pregnancy is critical to pro-
viding optimal therapy for both infected women and their children and to
preventing perinatal transmission. Therefore, prenatal HIV counseling and test-
ing with consent should be the standard of care for all pregnant women in the
United States (8–10 ).
• Enrollment of pregnant HIV-infected women; their HIV-exposed newborns; and
infected infants, children, and adolescents into clinical trials offers the best
means of determining safe and effective therapies.*
• Pharmaceutical companies and the federal government should collaborate to en-
sure that drug formulations suitable for administration to infants and children are
available at the time that new agents are being evaluated in adults.
• Although some information regarding the efficacy of antiretroviral drugs for chil-
dren can be extrapolated from clinical trials involving adults, concurrent clinical
trials for children are needed to determine the impact of the drug on specific
manifestations of HIV infection in children, including growth, development, and
neurologic disease. However, the absence of clinical trials addressing pediatric-
specific manifestations of HIV infection does not preclude the use of any
approved antiretroviral drug in children.
• All antiretroviral drugs approved for treatment of HIV infection may be used for
children when indicated—irrespective of labeling notations.
• Management of HIV infection in infants, children, and adolescents is rapidly
evolving and becoming increasingly complex; therefore, wherever possible,
management of HIV infection in children and adolescents should be directed by
a specialist in the treatment of pediatric and adolescent HIV infection. If this is not
possible, such experts should be consulted regularly.
• Effective management of the complex and diverse needs of HIV-infected infants,
children, adolescents, and their families requires a multidisciplinary team
approach that includes physicians, nurses, social workers, psychologists, nutri-
tionists, outreach workers, and pharmacists.
*In areas where enrollment in clinical trials is possible, enrolling the child in available trials
should be discussed with the caregivers of the child. Information about clinical trials for
HIV-infected adults and children can be obtained from the AIDS Clinical Trials Information
Service, telephone (800) 874-2572 ([800] TRIALS-A).
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• Determination of HIV RNA copy number and CD4+ T-lymphocyte levels is essen-
tial for monitoring and modifying antiretroviral treatment in infected children and
adolescents as well as adults; therefore, assays to measure these variables
should be made available.
• Health-care providers considering antiretroviral regimens for children and
adolescents should consider certain factors influencing adherence to therapy, in-
cluding a) availability and palatability of pediatric formulations; b) impact of the
medication schedule on quality of life, including number of medications,
frequency of administration, ability to co-administer with other prescribed medi-
cations, and need to take with or without food; c) ability of the child’s caregiver or
the adolescent to administer complex drug regimens and availability of re-
sources that might be effective in facilitating adherence; and d) potential for drug
interactions.
• The choice of antiretroviral regimens should include consideration of factors as-
sociated with possible limitation of future treatment options, including the
potential for the development of antiretroviral resistance.
• Monitoring growth and development is essential for the care of HIV-infected chil-
dren. Growth failure and neurodevelopmental deterioration may be specific
manifestations of HIV infection in children. Nutritional-support therapy is an
intervention that affects immune function, quality of life, and bioactivity of anti-
retroviral drugs.
Identification of Perinatal HIV Exposure
Appropriate treatment of HIV-infected infants requires HIV-exposed infants to be
identified as soon as possible, which can be best accomplished through the identifica-
tion of HIV-infected women before or during pregnancy. Universal HIV counseling and
voluntary HIV testing with consent are recommended as the standard of care for all
pregnant women in the United States by the Public Health Service (PHS), the Ameri-
can Academy of Pediatrics, and the American College of Obstetricians and Gyne-
cologists and is endorsed by the Working Group (8–10 ). 
Early identification of HIV-infected women is crucial for the health of such women
and for care of HIV-exposed and HIV-infected children. Knowledge of maternal HIV
infection during the antenatal period enables a) HIV-infected women to receive appro-
priate antiretroviral therapy and prophylaxis against opportunistic infections for their
own health; b) provision of antiretroviral chemoprophylaxis with ZDV during preg-
nancy, during labor, and to newborns to reduce the risk for HIV transmission from
mother to child (4,6,7 ); c) counseling of infected women about the risks for HIV trans-
mission through breast milk and advising against breastfeeding in the United States
and other countries where safe alternatives to breast milk are available (11 ); d) initia-
tion of prophylaxis against Pneumocystis carinii  pneumonia (PCP) in all HIV-exposed
infants beginning at age 4–6 weeks in accordance with PHS guidelines (12 ); and
e) early diagnostic evaluation of HIV-exposed infants to permit early initiation of ag-
gressive antiretroviral therapy in infected infants.
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If women are not tested for HIV during pregnancy, counseling and HIV testing
should be recommended during the immediate postnatal period. For newborns in
whom maternal serostatus was not determined during the prenatal or immediate
postpartum period, HIV antibody should be tested for following counseling and
consent of the mother. The HIV-exposure status of infants should be determined rap-
idly because the neonatal component of the recommended ZDV chemoprophylaxis
regimen should begin as soon as possible after birth and because PCP prophylaxis
should be initiated at age 4–6 weeks in all infants born to HIV-infected women. Those
infants who have been abandoned, are in the custody of the state, or have positive
toxicology screening tests should be considered at high risk for exposure to HIV, and
mechanisms to facilitate rapid HIV screening of such infants should be developed.
Diagnosis of HIV Infection in Infants
HIV infection can be definitively diagnosed in most infected infants by age 1 month
and in virtually all infected infants by age 6 months by using viral diagnostic assays. A
positive virologic test (i.e., detection of HIV by culture or DNA or RNA polymerase
chain reaction [PCR]) indicates possible HIV infection and should be confirmed by a
repeat virologic test on a second specimen as soon as possible after the results of the
first test become available. Diagnostic testing should be performed before the infant
is aged 48 hours, at age 1–2 months, and at age 3–6 months. Testing at age 14 days
also may be advantageous for early detection of infection. HIV-exposed infants should
be evaluated by or in consultation with a specialist in HIV infection in pediatric
patients.
HIV DNA PCR is the preferred virologic method for diagnosing HIV infection during
infancy. A meta-analysis of published data from 271 infected children indicated that
HIV DNA PCR was sensitive for the diagnosis of HIV infection during the neonatal
period. Thirty-eight percent (90% confidence interval [CI]=29%–46%) of infected chil-
dren had positive PCR tests by age 48 hours (13 ). No substantial change in sensitivity
during the first week of life was observed, but sensitivity increased rapidly during the
second week, with 93% of infected children (90% CI=76%–97%) testing positive by PCR
by age 14 days.
Assays that detect HIV RNA in plasma also may be useful for diagnosis of perinatal
infection and may prove to be more sensitive than DNA PCR for early diagnosis of HIV
infection in HIV-exposed infants (14 ). However, data are more limited regarding the
sensitivity and specificity of HIV RNA assays compared with HIV DNA PCR for early
diagnosis. 
HIV culture has a sensitivity similar to that of DNA PCR for the diagnosis of infection
(15 ). However, HIV culture is more complex and expensive to perform than DNA PCR,
and definitive results may not be available for 2–4 weeks. Although use of standard
and immune-complex–dissociated p24 antigen tests are highly specific for HIV infec-
tion and have been used to diagnose infection in children, the sensitivity of these tests
is less than the sensitivity of other HIV virologic tests. The use of p24 antigen testing
alone is not recommended to exclude infection or for diagnosis of infection in infants
aged <1 month because of a high frequency of false-positive assays during this time
(16 ).
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Initial testing is recommended by age 48 hours because nearly 40% of infected
infants can be identified at this time. Because of concerns regarding potential con-
tamination with maternal blood, blood samples from the umbilical cord should not be
used for diagnostic evaluations. Working definitions have been proposed for acquisi-
tion of HIV infection during the intrauterine and intrapartum periods. Infants who have
a positive virologic test at or before age 48 hours are considered to have early (i.e.,
intrauterine) infection, whereas infants who have negative virologic tests during the
first week of life and subsequent positive tests are considered to have late (i.e., intra-
partum) infection (17 ). Some researchers have proposed that infants with early
infection may have more rapid disease progression than those with late infection and
therefore should receive a more aggressive therapeutic approach (18,19 ). However,
recent data from prospective cohort studies have demonstrated that although early
differences in HIV RNA levels have been present between infants with positive HIV
culture within 48 hours of birth and those with a first positive culture after age 7 days,
these differences were no longer statistically significant after age 2 months (20 ). HIV
RNA copy number after the first month of life was more prognostic of rapid disease
progression than the time at which HIV culture tests were positive (20 ). Repeat diag-
nostic testing also can be considered at age 14 days in infants with negative tests at
birth, because the diagnostic sensitivity of virologic assays increases rapidly by age
2 weeks and early identification of infection would permit modification of antiretro-
viral therapy from the standard 6-week course of neonatal ZDV chemoprophylaxis to
more aggressive combination antiretroviral therapy.
Infants with initially negative virologic tests should be retested at age 1–2 months.
With increasing use of ZDV to reduce perinatal transmission, most HIV-exposed neo-
nates will receive 6 weeks of antiretroviral chemoprophylaxis. Although prophylactic
antiretroviral therapy theoretically could affect the predictive value of HIV virologic
testing in neonates, ZDV monotherapy did not delay the detection of HIV by culture in
infants in PACTG protocol 076 and has not decreased the sensitivity and predictive
values of many virologic assays (4,21 ). However, whether the current, more intensive
combination antiretroviral regimens women may receive during pregnancy for treat-
ment of their own HIV infection will affect diagnostic test sensitivity in their infants is
unknown.
HIV-exposed children who have had repeatedly negative virologic assays at birth
and at age 1–2 months should be retested again at age 3–6 months. HIV infection is
diagnosed by two positive HIV virologic tests performed on separate blood samples.
HIV infection can be reasonably excluded among children with two or more negative
virologic tests, two of which are performed at age ≥1 month, and one of those being
performed at age ≥4 months (12 ). Two or more negative HIV immunoglobulin G (IgG)
antibody tests performed at age >6 months with an interval of at least 1 month be-
tween the tests also can be used to reasonably exclude HIV infection among children
with no clinical evidence of HIV infection. HIV infection can be definitively excluded if
HIV IgG antibody is negative in the absence of hypogammaglobulinemia at age
18 months and if the child has both no clinical symptoms of HIV infection and negative
HIV virologic assays.
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Monitoring of Pediatric HIV Infection
Immunologic Parameters in Children
Clinicians interpreting CD4+ T-lymphocyte number for children must consider age
as a variable. CD4+ T-lymphocyte count and percentage values in healthy infants who
are not infected with HIV are considerably higher than those observed in uninfected
adults and slowly decline to adult values by age 6 years (22,23 ). A pediatric clinical
and immunologic staging system for HIV infection has been developed that includes
age-related definitions of immune suppression (Tables 1 and 2) (24 ). Although the
CD4+ absolute number that identifies a specific level of immune suppression changes
with age, the CD4+ percentage that defines each immunologic category does not.
Thus, a change in CD4+ percentage, not number, may be a better marker of identifying
disease progression in children. In infected children and adults, the CD4+ cell count
declines as HIV infection progresses, and patients with lower CD4+ cell counts have a
poorer prognosis than patients with higher counts (Table 3).
Because knowledge of immune status (i.e., CD4+ T-lymphocyte count and percent-
age) is essential when caring for HIV-infected infants and children, CD4+ T-lymphocyte
values should be obtained as soon as possible after a child has a positive virologic test
for HIV and every 3 months thereafter (25,26 ). Infected infants who have a thymic
defect lymphocyte immunophenotypic profile (i.e., CD4+ count <1,900/mm3 and CD8+
count >850/mm3) during the first 6 months of life have had more rapid HIV disease
progression than infants who do not have this profile (27 ). 
The CD4+ T-lymphocyte count or percentage value is used in conjunction with
other measurements to guide antiretroviral treatment decisions and primary prophy-
laxis for PCP after age 1 year. However, measurement of CD4+ cell values can be
associated with considerable intrapatient variation. Even mild intercurrent illness or
the receipt of vaccinations can produce a transient decrease in CD4+ cell number and
percentage; thus, CD4+ values are best measured when patients are clinically stable.
No modification in therapy should be made in response to a change in CD4+ cell val-
ues until the change has been substantiated by at least a second determination, with
a minimum of 1 week between measurements.
TABLE 1. 1994 Revised human immunodeficiency virus pediatric classification system:
immune categories based on age-specific CD4+ T-lymphocyte count and percentage*
Immune category
<12 mos 1–5 yrs 6–12 yrs
No./µL (%) No./µL (%) No./µL (%)
Category 1–
no suppression ≥1,500 (≥25%) ≥1,000 (≥25%) ≥500 (≥25%)
Category 2–
moderate
suppression 750–1,499 (15%–24%) 500–999 (15%–24%) 200–499 (15%–24%)
Category 3–
severe suppression <750 (<15%) <500 (<15%) <200 (<15%)
*Modified from: CDC. 1994 Revised classification system for human immunodeficiency virus
infection in children less than 13 years of age. MMWR 1994;43(no. RR-12):1–10.
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Category N: Not Symptomatic
Children who have no signs or symptoms considered to be the result of HIV
infection or who have only one of the conditions listed in category A.
Category A: Mildly Symptomatic
Children with two or more of the following conditions but none of the conditions
listed in categories B and C:





• Recurrent or persistent upper respiratory infection, sinusitis, or otitis media
Category B: Moderately Symptomatic
Children who have symptomatic conditions other than those listed for category
A or category C that are attributed to HIV infection. Examples of conditions in clini-
cal category B include but are not limited to the following:
• Anemia (<8 gm/dL), neutropenia (<1,000/mm3), or thrombocytopenia
(<100,000/mm
3
) persisting ≥30 days
• Bacterial meningitis, pneumonia, or sepsis (single episode)
• Candidiasis, oropharyngeal (i.e., thrush) persisting for >2 µοντησ ιν χηιλδρεν
αγεδ >6 µοντησ
• Cardiomyopathy
• Cytomegalovirus infection with onset before age 1 month
• Diarrhea, recurrent or chronic
• Hepatitis
• Herpes simplex virus (HSV) stomatitis, recurrent (i.e., more than two episodes
within 1 year)
• HSV bronchitis, pneumonitis, or esophagitis with onset before age 1 month
• Herpes zoster (i.e., shingles) involving at least two distinct episodes or more
than one dermatome
• Leiomyosarcoma




• Fever lasting >1 month
• Toxoplasmosis with onset before age 1 month
• Varicella, disseminated (i.e., complicated chickenpox)
Category C: Severely Symptomatic
Children who have any condition listed in the 1987 surveillance case definition
for acquired immunodeficiency syndrome, with the exception of LIP (which is a
category B condition).
*Modified from: CDC. 1994 Revised classification system for human immunodeficiency virus
infection in children less than 13 years of age. MMWR 1994;43(no. RR-12):1–10.
TABLE 2. 1994 Revised human immunodeficiency virus pediatric classification system:
clinical categories*
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HIV RNA in Children
Viral burden in peripheral blood can be determined by using quantitative HIV RNA
assays. During the period of primary infection in adults, HIV RNA copy number initially
rises to high peak levels. Coincident with the body’s humoral and cell-mediated im-
mune response, RNA levels decline by as much as 2–3 log10 copies to reach a stable
lower level (i.e., the virologic set-point) approximately 6–12 months following acute
infection, reflecting the balance between ongoing viral production and immune elimi-
nation (28,29 ). Several studies conducted among adults have indicated that infected
persons with lower HIV copy number at the time of RNA stabilization have slower
progression and improved survival compared with those with high HIV RNA set points
(30,31 ). On the basis of such data, recommendations for the use of HIV RNA copy
number in deciding to initiate and change antiretroviral therapy in infected adults
have been developed (5 ). These recommendations also are applicable to infected
adolescents, particularly those who have acquired HIV infection recently rather than
through perinatal infection. These recommendations also are likely to be applicable to
perinatally infected children aged >3 years.
The HIV RNA pattern in perinatally infected infants differs from that in infected
adults. High HIV RNA copy numbers persist in infected children for prolonged periods
(32,33 ). In one prospective study, HIV RNA levels generally were low at birth (i.e.,
<10,000 copies/mL), increased to high values by age 2 months (most infants had val-
ues >100,000 copies/mL, ranging from undetectable to nearly 10 million copies/mL),
and then decreased slowly; the mean HIV RNA level during the first year of life was
185,000 copies/mL (20 ). Additionally, in contrast to the adult pattern, after the first
year of life, HIV RNA copy number slowly declines over the next few years of life
(20,34–36 ). This pattern probably reflects the lower efficiency of an immature but de-
veloping immune system in containing viral replication and possibly a greater number
of HIV-susceptible cells.
TABLE 3. Association of baseline CD4+ T-lymphocyte percentage with long-term risk




     <5% 33 32 (97%)
 5%– 9% 29 22 (76%)
10%–14% 30 13 (43%)
15%–19% 41 18 (44%)
20%–24% 52 13 (25%)
25%–29% 49 15 (31%)
30%–34% 48  5 (10%)
    ≥35% 92 30 (33%)
*Data from the National Institute of Child Health and Human Development Intravenous Immu-
noglobulin Clinical Trial.
†Mean follow-up: 5.1 years.
§Includes 374 patients for whom baseline CD4+ T-lymphocyte percentage data were available.
Source: Mofenson L, Korelitz J, Meyer WA, et al. The relationship between serum human
immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent and long-term
mortality risk in HIV-1–infected children. J Infect Dis 1997;175:1029–38.
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Recent data indicate that high HIV RNA levels (i.e., >299,000 copies/mL) in infants
aged <12 months may be correlated with disease progression and death; however,
RNA levels in infants who have rapid disease progression and those who do not have
overlapped considerably (20,33 ). High RNA levels (i.e., levels of >100,000 copies/mL)
in infants also have been associated with high risk for disease progression and mor-
tality, particularly if CD4+ T-lymphocyte percentage is <15% (Tables 4 and 5) (35 ).
Similar findings have been reported in a preliminary analysis of data from PACTG
TABLE 4. Association of baseline human immunodeficiency virus (HIV) RNA copy
number with long-term risk for death in HIV-infected children*
Baseline (copies/mL)§ No. patients¶
Deaths†
No. (%)
Undetectable (i.e., ≤4,000)  25  6 (24%)
  4,001–  50,000  69 19 (28%)
 50,001– 100,000  33  5 (15%)
100,001– 500,000  72 29 (40%)
500,001–1,000,00  20  8 (40%)
      >1,000,000  35 25 (71%)
Total 254 92 (36%)
*Data from the National Institute of Child Health and Human Development Intravenous Immu-
noglobulin Clinical Trial.
†Mean follow-up: 5.1 years.
§Tested by NASBA assay (manufactured by Organon Teknika Corporation, Durham, North
Carolina) on frozen stored serum.
¶Mean age: 3.4 years.
Source: Mofenson L, Korelitz J, Meyer WA, et al. The relationship between serum human
immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent and long-term
mortality risk in HIV-1–infected children. J Infect Dis 1997;175:1029–38.
TABLE 5. Association of baseline human immunodeficiency virus (HIV) RNA copy








 ≥15% 103 15 (15%)
 <15%  24 15 (63%)
>100,000
 ≥15%  89 32 (36%)
 <15%  36 29 (81%)
*Data from the National Institute of Child Health and Human Development Intravenous Immu-
noglobulin Clinical Trial.
†Mean follow-up: 5.1 years.
§Tested by NASBA assay (manufactured by Organon Teknika Corporation, Durham, North
Carolina) on frozen stored serum.
¶Mean age: 3.4 years.
Source: Mofenson L, Korelitz J, Meyer WA, et al. The relationship between serum human
immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent and long-term
mortality risk in HIV-1–infected children. J Infect Dis 1997;175:1029–38.
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protocol 152 correlating baseline virologic data with risk for disease progression or
death during study follow-up (Table 6) (36 ). In this study, the relative risk for disease
progression was reduced by 54% for each 1 log10 decrease in baseline HIV RNA level.
Disease progression was documented in 11% of children aged <30 months at the time
the study was initiated (mean age: 1.1 years) who had baseline RNA in the lowest
quartile (e.g., from undetectable to 150,000 copies/mL) and in 52% of children with
baseline RNA in the highest quartile (e.g., >1,700,000 copies/mL) (36 ). Among chil-
dren aged ≥30 months at the time the study was initiated (mean age: 7.3 years), none
of those with baseline RNA in the lowest quartile (e.g., undetectable to 15,000 copies/
mL) compared with 34% of those in the highest quartile (e.g., >150,000 copies/mL) had
disease progression; children with RNA levels in the middle two quartiles (i.e., 15,000–
50,000 and 50,001–150,000 copies/mL) had similar progression rates (13% and 16%,
respectively). Data from children aged ≥30 months are similar to data from studies
among infected adults, in which the risk for disease progression substantially in-
creases when HIV RNA levels exceed 10,000–20,000 copies/mL (5 ).
Despite data indicating that high RNA levels are associated with disease progres-
sion, the predictive value of specific HIV RNA levels for disease progression and death
for an individual child is moderate (35 ). HIV RNA levels may be difficult to interpret
during the first year of life because levels are high and there is marked overlap in
levels between children who have and those who do not have rapid disease progres-
sion (32 ). Additional data indicate that CD4+ T-lymphocyte percentage and HIV RNA
copy number at baseline and changes in these parameters over time assist in deter-
mining the mortality risk in infected children, and the use of the two markers together
may more accurately define prognosis (35,36 ). Similar data and conclusions recently
have been reported from several studies involving infected adults (37–39 ).
TABLE 6. Association of baseline human immunodeficiency virus (HIV) RNA quartile
by age at entry with risk for disease progression or death during study follow-up




Disease progression or death
No. (%)
<30 months§  
  <1,000–  150,000 79  9 (11%)
 150,001–  500,000 66 13 (20%)
 500,001–1,700,000 76 29 (38%)
        >1,700,000 81 42 (52%)
≥30 months¶
 <1,000– 15,000 66  0 ( 0%)
 15,001– 50,000 54  7 (13%)
 50,001–150,000 80 13 (16%)
       >150,000 64 22 (34%)
*Data from Pediatric AIDS Clinical Trial Group protocol 152.
†Tested by the NASBA assay (manufactured by Organon Teknika Corporation, Durham, North
Carolina) on frozen stored plasma.
§Mean age: 1.1 years.
¶Mean age: 7.3 years.
Source: Palumbo PE, Raskino C, Fiscus S, et al. Disease progression in HIV-infected infants and
children: predictive value of quantitative plasma HIV RNA and CD4 lymphocyte count. JAMA
1998;279:756–61.
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Methodologic Considerations in the Interpretation and Comparability
of HIV RNA Assays
Most of the published data regarding HIV RNA in children have been obtained
using frozen, stored plasma and serum specimens. Some degradation of HIV RNA
occurs with specimen storage and delay in specimen processing; thus, the published
data on HIV RNA levels in infected children may not be directly comparable with data
obtained from specimens that undergo immediate testing (e.g., specimens obtained
for patient care). The HIV RNA assays used also differ by study. Therefore, direct
extrapolation of the predictive value of HIV RNA levels reported in published studies
to HIV RNA assays performed for clinical-care purposes may be problematic. Informa-
tion from ongoing prospective studies will assist in the interpretation of HIV RNA
levels among infected infants and children.
The use of HIV RNA assays for clinical purposes requires specific considerations
(40 ), which are discussed more completely elsewhere (5 ). Several different methods
can be used for quantitating HIV RNA, each with different levels of sensitivity;
although the results of the assays are correlated, the absolute HIV RNA copy number
obtained from a single specimen tested by two different assays can differ by twofold
(0.3 log10) or more. For example, plasma RNA measured by the quantitative PCR assay
(Amplicor HIV-1 Monitor, manufactured by Roche Diagnostics Systems, Nutley, New
Jersey) yields absolute values approximately twice (0.3 log10) those obtained using a
signal amplification, branched-chain DNA assay (Quantiplex®, manufactured by Chi-
ron Corporation, Emeryville, California) (5,41,42 ). Similarly, plasma RNA measured by
the nucleic acid sequence-based amplification assay (NASBA®, manufactured by Or-
ganon Technika, Durham, North Carolina) yields absolute values approximately twice
those obtained using the Quantiplex® assay but values relatively comparable with
those obtained using the Amplicor HIV-1 Monitor assay (41–43 ). Therefore, one HIV
RNA assay method should be used consistently for monitoring each patient. Choice of
HIV RNA assay, particularly for young children, may be influenced by the amount of
blood required for the assay. The NASBA® assay requires the least amount of blood
(i.e., 100 µL of plasma), followed by the Amplicor HIV-1 Monitor (i.e., 200 µL of
plasma) and the Quantiplex® assays (i.e., 1 mL of plasma).
Biologic variation in HIV RNA levels within one person is well documented, and
repeated measurement of HIV RNA levels in a clinically stable infected adult can vary
by as much as threefold (0.5 log10) in either direction over the course of a day or on
different days (5,39,44 ). This biologic variation may be greater in infected infants and
young children. In children with perinatally acquired HIV infection, RNA copy number
slowly declines even without therapy during the first several years after birth,
although it persists at higher levels than those observed in most infected adults
(20,34,35 ). This decline is most rapid during the first 12–24 months after birth, with an
average decline of approximately 0.6 log10 per year; a slower decline continues until
approximately age 4–5 years (average decline of 0.3 log10 per year). This inherent bio-
logic variability must be considered when interpreting changes in RNA copy number
in children. Thus, only changes greater than fivefold (0.7 log10) in infants aged
<2 years and greater than threefold (0.5 log10) in children aged ≥2 years after repeated
testing should be considered reflective of a biologically and clinically substantial
change. To reduce the impact of assay variability in the clinical management of
patients, two samples can be obtained at baseline and the average of the two values
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used for comparison with future tests. No alteration in therapy should be made as a
result of a change in HIV copy number unless the change is confirmed by a second
measurement. Because of the complexities of HIV RNA testing and the age-related
changes in HIV RNA in children, interpretation of HIV RNA levels for clinical decision-
making should be done by or in consultation with an expert in pediatric HIV infection.
Specific Issues in Antiretroviral Therapy
for HIV-Infected Adolescents
Adult guidelines for antiretroviral therapy are appropriate for post-pubertal adoles-
cents because HIV-infected adolescents who were infected sexually or through
injecting-drug use during adolescence follow a clinical course that is more similar to
that of adults than to that of children (5 ). The immunopathogenesis and virologic
course of HIV infection in adolescents is being defined. Most adolescents have been
infected during their teenage years and are in an early stage of infection, making them
ideal candidates for early intervention. A limited but increasing number of HIV-
infected adolescents are long-term survivors of HIV infection acquired perinatally or
through blood products as young children. Such adolescents may have a unique clini-
cal course that differs from that of adolescents infected later in life (45 ). Because
many adolescents with HIV infection are sexually active, issues associated with con-
traception and prevention of HIV transmission should be discussed between the
health-care provider and the adolescent.
Dosage for medications for HIV infection and opportunistic infections should be
prescribed according to Tanner staging of puberty (46 ) and not on the basis of age
(25 ). Adolescents in early puberty (i.e., Tanner Stage I and II) should be administered
doses using pediatric schedules, whereas those in late puberty (i.e., Tanner Stage V)
should follow adult dosing schedules. Youth who are in their growth spurt (i.e., in
females, Tanner Stage III and in males, Tanner Stage IV) should be closely monitored
for medication efficacy and toxicity when using adult or pediatric dosing guidelines.
Puberty is a time of somatic growth and sex differentiation, with females develop-
ing more body fat and males more muscle mass. Although these physiologic changes
theoretically could affect drug pharmacokinetics (especially for drugs with a narrow
therapeutic index that are used in combination with protein-bound medicines or he-
patic enzyme inducers or inhibitors), no clinically consequential impact has been
noted with nucleoside analogue reverse transcriptase inhibitor (NRTI) antiretroviral
drugs (47 ). Clinical experience with protease inhibitors and non-nucleoside reverse
transcriptase inhibitor antiretroviral drugs is more limited.
Specific Issues of Adherence for HIV-Infected Children
and Adolescents
Lack of adherence to prescribed regimens and subtherapeutic levels of antiretro-
viral medications may enhance the development of drug resistance. Data indicate
that the development of resistance to one of the available protease inhibitor
antiretrovirals may reduce susceptibility to some or all of the other available protease
inhibitor drugs, thus substantially reducing subsequent treatment options. Therefore,
education of infected children and/or their caregivers regarding the importance of
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compliance with the prescribed drug regimen is necessary when therapy is initiated
and should be reinforced during subsequent visits. Many strategies can be used to
increase medication adherence, including intensive patient education over several vis-
its before therapy is initiated, the use of cues and reminders for administering drugs,
development of patient-focused treatment plans to accommodate specific patient
needs, and mobilization of social and community support services.
Adherence to drug regimens is especially problematic for children. Infants and
young children are dependent on others for administration of medication; thus,
assessment of the capacity for adherence to a complex multidrug regimen requires
evaluation of the caregivers and their environments and the ability and willingness of
the child to take the drug. Liquid formulations or formulations suitable for mixing with
formula or food are necessary for administration of oral drugs to young children. Lack
of palatability of such formulations can be problematic depending on the child’s will-
ingness and ability to accept and retain the medication. Absorption of some anti-
retroviral drugs can be affected by food, and attempting to time the administration of
drugs around meals can be difficult for caregivers of young infants who require fre-
quent feedings. Many other barriers to adherence to drug regimens exist for children
and adolescents with HIV infection. For example, unwillingness of the caregivers to
disclose their child’s HIV infection status to others may create specific problems,
including reluctance of caregivers to fill prescriptions in their home neighborhood,
hiding or relabeling medications to maintain secrecy within the home, reduction of
social support (a variable associated with diminished treatment adherence), and a ten-
dency to eliminate midday doses when the parent is away from the home or the child
is at school.
A comprehensive assessment of adherence issues should be instituted for all chil-
dren in whom antiretroviral treatment is considered; evaluations should include
nursing, social, and behavioral assessments. Intensive follow-up is required particu-
larly during the critical first few months after therapy is started; patients should be
seen frequently to assess adherence, drug tolerance, and virologic response. Coordi-
nated, comprehensive, family-centered systems of care often can address many of the
daily problems facing families that may affect adherence to complex medical regi-
mens. For some families, certain issues (e.g., a safe physical environment and
adequate food and housing) may take priority over medication administration and
need to be resolved. Case managers, mental-health counselors, peer educators, out-
reach workers, and other members of the multidisciplinary team often may be able to
address specific barriers to adherence.
HIV-infected adolescents have specific adherence problems. Comprehensive sys-
tems of care are required to serve both the medical and psychosocial needs of
HIV-infected adolescents, who are frequently inexperienced with health-care systems.
Many HIV-infected adolescents face challenges in adhering to medical regimens for
reasons that include a) denial and fear of their HIV infection; b) misinformation; c) dis-
trust of the medical establishment; d) fear and lack of belief in the effectiveness of
medications; e) low self-esteem; f) unstructured and chaotic lifestyles; and g) lack of
familial and social support. Treatment regimens for adolescents must balance the goal
of prescribing a maximally potent antiretroviral regimen with realistic assessment of
existing and potential support systems to facilitate adherence.
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Developmental issues make caring for adolescents unique. The adolescent’s
approach to illness is often different from that of adults. The concrete thought
processes of adolescents make it difficult for them to take medications when they are
asymptomatic, particularly if the medications have side effects. Adherence with com-
plex regimens is particularly challenging at a time of life when adolescents do not
want to be different from their peers. Further difficulties face adolescents who live
with parents to whom they have not yet disclosed their HIV status and those who are
homeless and have no place to store medicine.
TREATMENT RECOMMENDATIONS
Initiation of Antiretroviral Therapy
General Considerations
Antiretroviral therapy has provided substantial clinical benefit to HIV-infected chil-
dren with immunologic or clinical symptoms of HIV infection. Studies have dem-
onstrated substantial improvements in neurodevelopment, growth, and immunologic
and/or virologic status with initiation of ZDV, didanosine (ddI), lamivudine (3TC), or
stavudine monotherapy (48–53 ). More recent pediatric trials of symptomatic children
who have not previously received antiretrovirals have demonstrated that combination
therapy with either ZDV and 3TC or ZDV and ddI is clinically, immunologically, and
virologically superior to monotherapy with ddI or ZDV as initial therapy (36,54,55 ). A
trial involving children who have previously received antiretrovirals has demonstrated
that combination therapy that includes a protease inhibitor is virologically and immu-
nologically superior to dual nucleoside combination therapy (56 ).
Data from clinical trials that address the effectiveness of antiretroviral therapy in
asymptomatic infants and children with normal immune function are not available.
However, initiation of therapy early in the course of HIV infection, including during the
period of primary infection in the neonate, is theoretically advantageous. Control of
viral replication in perinatally infected infants is inadequate, as demonstrated by the
high levels of HIV RNA that are observed during the first 1–2 years of life following
perinatal infection. Initiation of aggressive antiretroviral therapy during this early pe-
riod of viral replication could theoretically preserve immune function, diminish viral
dissemination, lower the viral set point, and result in improved clinical outcome.
In a preliminary study of early treatment of children, six HIV-infected infants aged
2–4 months were placed on a regimen of ZDV, ddI, and nevirapine; baseline HIV RNA
levels were 40,000–1,500,000 copies per mL. Five of six infants had an early virologic
response with a drop in RNA PCR to <10,000 copies/mL by day 14, and two of the
infants maintained undetectable levels of HIV RNA through 168 days of therapy (57 ).
These two children had persistently negative HIV cultures, undetectable RNA levels,
and became HIV antibody negative, although HIV DNA PCR remained positive. Clinical
trials are ongoing to assess the virologic, immunologic, and clinical response of
young infants to early, aggressive antiretroviral therapy with three or four antiretro-
viral agents.
The theoretical problems with early therapy include the potential for short- and
long-term adverse effects—particularly for drugs being administered to infants aged
Vol. 47 / No. RR-4 MMWR 15
<6 months, for whom information on pharmacokinetics, drug dosing, and safety is
limited. These concerns are particularly relevant because life-long administration of
therapy is likely to be necessary for HIV-infected infants. If viral replication is not sup-
pressed, ongoing viral mutation is likely to result in the development of antiretroviral
resistance, curtailing the duration of benefit that early therapy might confer and
potentially limiting future treatment options. Therefore, intensive education of care-
givers and patients about the importance of adherence to the prescribed treatment
regimen should be provided before therapy is initiated so that a) potential problems
and solutions can be identified and b) frequent follow-up can be provided to assess
virologic response to therapy, drug tolerance, and adherence.
When to Initiate Therapy
Antiretroviral therapy is recommended for HIV-infected children with clinical symp-
toms of HIV infection (i.e., those in clinical categories A, B, or C) (Table 2) or evidence
of immune suppression (i.e., those in immune categories 2 or 3) (Table 1)—regardless
of the age of the child or viral load (Table 7). Clinical trial data from both adults and
children have demonstrated that antiretroviral therapy in symptomatic patients slows
clinical and immunologic disease progression and reduces mortality (54,55,58 ). 
• Clinical symptoms associated with HIV infection (i.e., clinical categories A, B,
or C [Table 2]).
• Evidence of immune suppression, indicated by CD4+ T-lymphocyte absolute
number or percentage (i.e., immune category 2 or 3 [Table 1]).
• Age <12 months—regardless of clinical, immunologic, or virologic status.
• For asymptomatic children aged ≥1 year with normal immune status, two
options can be considered:
– Preferred Approach
Initiate therapy—regardless of age or symptom status.
– Alternative Approach
Defer treatment in situations in which the risk for clinical disease pro-
gression is low and other factors (e.g., concern for the durability of
response, safety, and adherence) favor postponing treatment. In such
cases, the health-care provider should regularly monitor virologic, immu-
nologic, and clinical status. Factors to be considered in deciding to initiate
therapy include the following:
– High or increasing HIV RNA copy number.
– Rapidly declining CD4+ T-lymphocyte number or percentage to values
approaching those indicative of moderate immune suppression (i.e., im-
mune category 2 [Table 1]).
– Development of clinical symptoms.
*Indications for initiation of antiretroviral therapy in post-pubertal HIV-infected adolescents
should follow the adult guidelines (Office of Public Health and Science, Department of Health
and Human Services. Availabililty of report of NIH panel to define principles of therapy of HIV
infection and guidelines for the use of antiretroviral agents in HIV-infected adults. Federal
Register 1997;62:33417–8.)
TABLE 7. Indications for initiation of antiretroviral therapy in children with human
immunodeficiency virus (HIV) infection*
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Ideally, antiretroviral therapy should be initiated in all HIV-infected infants aged
<12 months as soon as a confirmed diagnosis is established—regardless of clinical or
immunologic status or viral load. HIV-infected infants aged <12 months are consid-
ered at high risk for disease progression, and the predictive value of immunologic and
virologic parameters to identify infants who will have rapid progression is less than
that for older children. Identification of infection during the first few weeks of life per-
mits clinicians to initiate antiretroviral therapy or intensify ongoing antiretroviral
therapy used for chemoprophylaxis of perinatal transmission during the initial phases
of primary infection. However, clinical trial data documenting therapeutic benefit from
this approach are not available, and information on drug dosing in neonates is limited.
Because resistance to antiretroviral drugs (particularly protease inhibitors) can de-
velop rapidly when drug concentrations fall below therapeutic levels (either as a result
of inadequate dosage or incomplete adherence), issues associated with adherence
should be fully assessed and discussed with the HIV-infected infant’s caregivers be-
fore the decision to initiate therapy is made.
Two general approaches for initiating therapy in asymptomatic children aged
≥1 year were outlined by the Working Group. The first approach would be to initiate
therapy in all HIV-infected children, regardless of age or symptom status. Such an
approach would ensure a) treatment of infected children as early as possible in the
course of disease and b) intervention before immunologic deterioration. Data from
prospective cohort studies indicate that most HIV-infected infants will have clinical
symptoms of infection by age 1 year (59,60 ). Most asymptomatic infected children
aged >1 year also have CD4+ T-lymphocyte percentages of <25% (60 ), which is indica-
tive of immunosuppression (Table 1) and warrants antiretroviral therapy.
An alternative approach would be to defer treatment in asymptomatic children
aged ≥1 year with normal immune status in situations in which the risk for clinical
disease progression is low (e.g., low viral load) and when other factors (e.g., concern
for adherence, safety, and persistence of antiretroviral response) favor postponing
treatment. In such cases, the health-care provider should regularly monitor virologic,
immunologic, and clinical status. Factors to be considered in deciding when to initiate
therapy include a) high or increasing HIV RNA levels, b) rapidly declining CD4+
T-lymphocyte number or percentage to values approaching those indicative of moder-
ate immune suppression (i.e., immune category 2 [Table 1]), or c) development of
clinical symptoms. The level of HIV RNA considered indicative of increased risk for
disease progression is not well defined for young children. Regardless of age, any
child with HIV RNA levels of >100,000 copies/mL is at high risk for mortality (Table 4),
and antiretroviral therapy should be initiated—regardless of clinical or immune status.
HIV RNA levels in asymptomatic children aged ≥30 months that are the same as levels
for which there are treatment recommendations for HIV-infected adults (e.g., >10,000–
20,000 copies/mL) also may indicate the need to initiate treatment (Table 6). In
addition, any child with HIV RNA levels that demonstrate a substantial increase (more
than a 0.7 log10 [fivefold] increase for children aged <2 years and more than a 0.5 log10
[threefold] increase for those aged ≥2 years) on repeated testing should be offered
therapy—regardless of clinical or immunologic status or absolute level of viral load.
These recommendations are based on limited data and may need revision as more
information becomes available.
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Issues associated with adherence to treatment are especially important in consid-
ering whether and when to initiate therapy. Antiretroviral therapy is most effective in
patients who have never received therapy and who therefore are less likely to have
antiretroviral-resistant viral strains. Lack of adherence to prescribed regimens and
subtherapeutic levels of antiretroviral medications, particularly protease inhibitors,
may enhance the development of drug resistance. Participation by the caregivers and
child in the decision-making process is crucial, especially in situations for which de-
finitive data concerning efficacy are not available.
Choice of Initial Antiretroviral Therapy
Combination therapy is recommended for all infants, children, and adolescents
who are treated with antiretroviral agents (Table 8). When compared with mono-
therapy, combination therapy a) slows disease progression and improves survival,
b) results in a greater and more sustained virologic response, and c) delays develop-
ment of virus mutations resistant to the drugs being used. Monotherapy with the
currently available antiretroviral drugs is no longer recommended to treat HIV infec-
tion. ZDV monotherapy is appropriate, however, when used in infants of indeter-
minate HIV status during the first 6 weeks of life to prevent perinatal HIV transmission.
Infants who are identified as being HIV-infected while receiving ZDV chemoprophy-
laxis should be changed to a combination antiretroviral drug regimen.
Aggressive antiretroviral therapy for primary perinatal infection with three drugs is
recommended because it provides the best opportunity to preserve immune function
and delay disease progression. The goal of antiretroviral therapy is to maximally sup-
press viral replication, preferably to undetectable levels. Based on clinical trials
involving infected adults, the preferred regimen is combination therapy with two
NRTIs and one protease inhibitor. Although these combinations have had limited
evaluation in clinical trials involving children, they can reduce HIV RNA to undetect-
able levels in some children (61,62 ). An interim analysis from a clinical trial of children
(i.e., PACTG protocol 338) has demonstrated that therapy with drug combinations that
include a protease inhibitor is more effective than therapy with two NRTI antiretroviral
drugs in reducing viral load to undetectable levels and increasing CD4+ T-lymphocyte
number (56 ). New antiretroviral drugs and combinations are being studied in infected
adults and children. Other drug combinations that demonstrate sustainable viral load
suppression and acceptable toxicity and dosing profiles most likely will become avail-
able, which will increase treatment options for children in the future.
Protease inhibitors with formulations appropriate for infants and children who
cannot swallow pills include nelfinavir (Viracept®, manufactured by Agouron Pharma-
ceuticals, Inc., La Jolla, California), available in a powder formulation that can be
mixed with water or food, and ritonavir (Norvir®, manufactured by Abbott Laborato-
ries, North Chicago, Illinois), available in a liquid formulation. Optimal dosing of these
drugs in children aged <2 years is not known but is being evaluated in clinical trials
(See Appendix). Indinavir (Crixivan®, manufactured by Merck and Company, Inc.,
West Point, Pennsylvania) and saquinavir (hard gel capsule, Invirase, and soft gel
capsule, Fortovase, manufactured by Hoffman-LaRoche, Inc., Nutley, New Jersey)
are not available in liquid formulations. Indinavir is recommended for consideration
for children who can tolerate swallowing capsules. Optimal dosing of these drugs
in infants and children is not known but is being evaluated in clinical trials (See
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Preferred Regimen
Evidence of clinical benefit and sustained suppression of HIV RNA in clinical
trials in HIV-infected adults; clinical trials in HIV-infected children are ongoing.
• One highly active protease inhibitor plus two nucleoside analogue reverse
transcriptase inhibitors (NRTIs)
– Preferred protease inhibitor for infants and children who cannot swallow
pills or capsules: nelfinavir or ritonavir. Alternative for children who can
swallow pills or capsules: indinavir.
– Recommended dual NRTI combinations: the most data on use in children
are available for the combinations of zidovudine (ZDV) and dideoxyinosine
(ddI) and for ZDV and lamivudine (3TC). More limited data are available for
the combinations of stavudine (d4T) and ddI, d4T and 3TC, and ZDV and
zalcitabine (ddC)*
Alternative Regimen
Less likely to produce sustained HIV RNA suppression in infected adults; the
combination of nevirapine, ZDV, and ddI produced substantial and sustained sup-
pression of viral replication in two of six infants first treated at age <4 months.†
• Nevirapine§ and two NRTIs
Secondary Alternative Regimen
Clinical benefit demonstrated in clinical trials involving infected adults and/or
children, but initial viral suppression may not be sustained.
• Two NRTIs
Not Recommended
Evidence against use because of overlapping toxicity and/or because use may
be virologically undesirable.
• Any monotherapy¶
• d4T and ZDV
• ddC and ddI
• ddC and d4T
• ddC and 3TC
*ddC is not available in a liquid preparation commercially, although a liquid formulation is
available through a compassionate use program of the manufacturer (Hoffman-LaRoche Inc.,
Nutley, New Jersey). ZDV and ddC is a less preferred choice for use in combination with a
protease inhibitor.
†Source: Luzuiraga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine,
didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
N Engl J Med 1997;336:1343–9.
§A liquid preparation of nevirapine is not available commercially, but is available through a
compassionate use program of the manufacturer (Boehringer Ingelheim Pharmaceuticals, Inc.,
Ridgefield, Connecticut).
¶Except for ZDV chemoprophylaxis administered to HIV-exposed infants during the first 6 weeks
of life to prevent perinatal HIV transmission; if an infant is identified as HIV-infected while
receiving ZDV prophylaxis, therapy should be changed to a combination antiretroviral drug
regimen.
TABLE 8. Recommended antiretroviral regimens for initial therapy for human
immunodeficiency virus (HIV) infection in children
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Appendix). The hard-gel capsule formulation of saquinavir (Invirase) has limited
bioavailability and thus is not recommended for use with two NRTIs. Some studies
have indicated substantial increases in saquinavir drug levels when co-administered
with other protease inhibitors (e.g., ritonavir) or other drugs that inhibit the cyto-
chrome P450 enzyme system. However, data regarding such combinations in children
are not available. The soft-gel formulation of saquinavir (Fortovase) with enhanced
bioavailability has been approved by the Food and Drug Administration (FDA) for
treatment of HIV infection in adults; however, data regarding appropriate dosing of
this formulation in pediatric patients are not available.
Alternative regimens, although not ideal, may be considered for initial therapy in
circumstances in which the caregiver has concerns regarding the feasibility of adher-
ence to a complex drug regimen or when the patient and caregivers prefer an altern-
ative regimen. Alternative regimens have been clinically beneficial in adult and pedi-
atric patients, but these regimens may not suppress viral load to below detectable
levels as consistently as does combination therapy with two NRTIs and a protease
inhibitor. Such alternative regimens include combination regimens of two NRTIs with
nevirapine substituted for the protease inhibitor or two NRTIs alone. However, drug
regimens that do not result in sustained viral suppression may result in the develop-
ment of viral resistance to the drugs being used.
The initial antiretroviral regimen chosen for infected infants theoretically could be
influenced by the antiretroviral regimen their mother may have received during preg-
nancy. However, data from PACTG protocol 076 indicate that ZDV resistance did not
account for most infants who became infected despite maternal ZDV treatment (63 ),
and data from PACTG protocol 185 indicate that duration of prior ZDV therapy in
women with advanced HIV disease, many of whom received prolonged ZDV before
pregnancy, was not associated with diminished ZDV efficacy for reduction of trans-
mission (64 ). Data do not suggest that the antiretroviral regimen for infected infants
should be chosen on the basis of maternal antiretroviral use. However, continuing to
monitor the frequency of perinatal transmission of antiretroviral-resistant HIV isolates
is crucial, because maternal therapy with multiple antiretroviral agents is becoming
more common and the prevalence of resistant viral strains in the HIV-infected popula-
tion may increase over time.
Issues Regarding Antiretroviral Dosing in Neonates
Data regarding the appropriate dosing of antiretroviral drugs in neonates are lim-
ited; ZDV is the best studied antiretroviral drug in this age group. The recommended
ZDV dosage for infants was derived from pharmacokinetics studies performed in full-
term infants (65 ). Because ZDV is primarily cleared through hepatic metabolism (i.e.,
glucuronidation), which is immature in neonates, the half-life and clearance of ZDV
are prolonged in neonates compared with older infants, thus requiring adjustments in
dosing (See Appendix).
Premature infants have even greater immaturity in hepatic metabolic function than
do full-term infants, and further prolongation in clearance has been documented in
very premature infants (e.g., those born before 34 weeks’ gestation) (66 ). Appropriate
ZDV dosing for premature infants has not been defined but is being evaluated in a
phase I clinical trial of premature infants born before 34 weeks’ gestation (i.e., PACTG
protocol 331) (See Appendix).
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The safety and pharmacokinetics of 3TC administered alone or in combination with
ZDV in pregnant women and administered for 1 week to their newborns have been
evaluated (67,68 ). Clearance was prolonged in these infants. On the basis of data
from this study, the dose recommended for use in newborns is half the dose recom-
mended in older children (See Appendix). No data are available regarding 3TC
pharmacokinetics among infants aged 2–6 weeks, and the exact age at which 3TC
clearance begins to approximate that in older children is not known.
Nevirapine administration to HIV-infected pregnant women during labor and as a
single dose to their newborns at age 2–3 days has been studied in a phase I trial (69 ).
The half-life of nevirapine was prolonged in neonates compared with that in older
children, indicating that some modification of nevirapine dosage is required for ad-
ministration to neonates (See Appendix).
Although phase I studies of several protease inhibitors (i.e., indinavir, ritonavir, nel-
finavir, or saquinavir in combination with ZDV and 3TC) in pregnant infected women
and their infants are ongoing in the United States, no data are available regarding
drug dosage, safety, and tolerance of any of the protease inhibitors in neonates.
Changing Antiretroviral Therapy
When to Change Antiretroviral Therapy
The following three reasons warrant a change in antiretroviral therapy: a) failure of
the current regimen with evidence of disease progression based on virologic, immu-
nologic, or clinical parameters; b) toxicity or intolerance to the current regimen; and
c) new data demonstrating that a drug or regimen is superior to the current regimen
(Table 9). When therapy must be changed because of treatment failure or suboptimal
response to treatment, clinicians should work with families to assess the possible con-
tribution of adherence problems to the failure of the current regimen. Issues regarding
adherence should be addressed to increase the likelihood of a successful outcome
when initiating a new therapy. These issues are best addressed before therapy is insti-
tuted and need to be reinforced during therapy.
Intensive family education, training in the administration of prescribed medica-
tions, and discussion of the importance of adherence to the drug regimen should be
completed before initiation of new treatment. In addition, frequent patient visits and
intensive follow-up during the initial months after a new antiretroviral regimen is
started are needed to support and educate the family and to monitor adherence, toler-
ance, and virologic response to the new regimen.
Virologic Considerations for Changing Therapy
Information is limited regarding HIV RNA response to antiretroviral therapy in in-
fants and young children. However, the general virologic principles underlying the use
of antiretroviral therapy are similar for all HIV-infected persons. Because HIV RNA
monitoring is critical for the management of infected children, Working Group mem-
bers used the available data and clinical experience when definitive data were not
available to make the following recommendations. These recommendations may
require modification as new information becomes available.
Ideally, antiretroviral therapy should maximally suppress viral replication to below
levels capable of being detected with HIV RNA assays—which may not always be
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Virologic Considerations*
• Less than a minimally acceptable virologic response after 8–12 weeks of ther-
apy. For children receiving antiretroviral therapy with two nucleoside analogue
reverse transcriptase inhibitors (NRTIs) and a protease inhibitor, such a re-
sponse is defined as a <10-fold (1.0 log10) decrease from baseline HIV RNA
levels. For children who are receiving less potent antiretroviral therapy (i.e.,
dual NRTI combinations), an insufficient response is defined as a less than five-
fold (0.7 log10) decrease in HIV RNA levels from baseline.
• HIV RNA not suppressed to undetectable levels after 4–6 months of antiretro-
viral therapy.
†
• Repeated detection of HIV RNA in children who initially responded to anti-
retroviral therapy with undetectable levels.
§
• A reproducible increase in HIV RNA copy number among children who have
had a substantial HIV RNA response but still have low levels of detectable HIV
RNA. Such an increase would warrant change in therapy if, after initiation of
the therapeutic regimen, a greater than threefold (0.5 log10) increase in copy
number for children aged ≥2 years and a greater than fivefold (0.7 log10) in-
crease is observed for children aged <2 years.
Immunologic Considerations*
• Change in immunologic classification (Table 1).¶
• For children with CD4+ T-lymphocyte percentages of <15% (i.e., those in im-
mune category 3), a persistent decline of five percentiles or more in CD4+ cell
percentage (e.g., from 15% to 10%).
• A rapid and substantial decrease in absolute CD4+ T-lymphocyte count (e.g., a
>30% decline in <6 months).
Clinical Considerations
• Progressive neurodevelopmental deterioration.
• Growth failure defined as persistent decline in weight-growth velocity despite
adequate nutritional support and without other explanation.
• Disease progression defined as advancement from one pediatric clinical cate-
gory to another (e.g., from clinical category A to clinical category B).**
 * At least two measurements (taken 1 week apart) should be performed before considering a change in
therapy.
† The initial HIV RNA level of the child at the start of therapy and the level achieved with therapy should
be considered when contemplating potential drug changes. For example, an immediate change in therapy
may not be warranted if there is a sustained 1.5 to 2.0 log10 decrease in HIV RNA copy number, even if
RNA remains detectable at low levels.
§ More frequent evaluation of HIV RNA levels should be considered if the HIV RNA increase is limited (e.g.,
if when using an HIV RNA assay with a lower limit of detection of 1,000 copies/mL, there is a ≤0.7 log10
increase from undetectable to approximately 5,000 copies/mL in an infant aged <2 years).
¶ Minimal changes in CD4+ T-lymphocyte percentile that may result in change in immunologic category
(e.g., from 26% to 24%, or 16% to 14%) may not be as concerning as a rapid substantial change in CD4+
percentile within the same immunologic category (e.g., a drop from 35% to 25%).
** In patients with stable immunologic and virologic parameters, progression from one clinical category to
another may not represent an indication to change therapy. Thus, in patients whose disease progression
is not associated with neurologic deterioration or growth failure, virologic and immunologic
considerations are important in deciding whether to change therapy.
TABLE 9. Considerations for changing antiretroviral therapy for human immuno-
deficiency virus (HIV)-infected children
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achievable in HIV-infected children. Perinatally infected children generally have high
HIV RNA levels, and clinical benefit may be observed with decrements in HIV RNA lev-
els that do not result in undetectable levels. However, failure to maximally suppress
replication may be associated with increased probability of viral mutations and the
emergence of drug resistance. Consideration of the implications of changing regi-
mens and the choice of new drugs should include an acknowledgment of the potential
for limiting the patient’s future options for potent therapy.
Consensus recommendations have been developed using plasma HIV RNA meas-
urements to guide changes in antiretroviral therapy for HIV-infected adults (5 ). The
recommendations for adults state that health-care providers should consider chang-
ing therapy if a) HIV RNA levels drop less than threefold (0.5 log10) after 4 weeks of
therapy and less than 10-fold (1.0 log10) after 8 weeks of therapy or b) HIV RNA has not
decreased to undetectable levels after 4–6 months of therapy. Because HIV RNA levels
in infants who are perinatally infected are high compared with levels observed when
therapy is initiated in most infected adults, the initial virologic response of infected
infants and young children to initiation of antiretroviral therapy may take longer than
observed in adults (i.e., 8–12 weeks). In addition, suppression of HIV RNA to undetect-
able levels may be achieved less often than has been reported for infected adults
despite potent combination therapy with two NRTIs and a protease inhibitor. There-
fore, virologic indications for changing therapy in infected children differ slightly from
those recommended for infected adults. Adult guidelines should be followed for
infected adolescents.
Virologic response should be initially assessed 4 weeks after therapy is initiated.
However, the time required to achieve maximal virologic response to therapy may
vary depending on the specific baseline HIV RNA value at the time of starting therapy.
If baseline HIV RNA levels are high (i.e., >1,000,000 copies/mL), virologic response
may not be observed until 8–12 weeks after initiating antiretroviral therapy. However,
if baseline HIV RNA levels are more similar to those observed in untreated infected
adults (i.e., <100,000 copies/mL), initial response should be observed within 4 weeks
following initiation of therapy. After a maximal virologic response is achieved, HIV
RNA levels should be measured at least every 3 months to monitor continued
response to therapy. At least two measurements (taken 1 week apart) should be per-
formed before considering a change in therapy. The following situations may indicate
a need for change in therapy in infected children:
• Less than a minimally acceptable virologic response after 8–12 weeks of therapy.
For children receiving antiretroviral therapy with two NRTIs and a protease
inhibitor, such a response is defined as a <10-fold (1.0 log10) decrease from base-
line HIV RNA levels. For children who are receiving less potent antiretroviral
therapy (i.e., dual NRTI combinations), an insufficient response is defined as a
less than fivefold (0.7 log10) decrease in HIV RNA levels from baseline.
• HIV RNA not suppressed to undetectable levels after 4–6 months of antiretroviral
therapy. However, although suppression of HIV RNA to undetectable levels and
maintenance for prolonged periods is desirable, few data among children indi-
cate that such suppression is always achievable. In addition, the number of
alternative therapeutic regimens for children is limited. The initial HIV RNA level
of the child at the start of therapy and the level achieved with therapy should be
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considered when contemplating potential drug changes. For example, an imme-
diate change in therapy may not be warranted if there is a sustained 1.5 to
2.0 log10 fall in HIV RNA copy number, even if RNA remains detectable at low
levels.
• Repeated detection of HIV RNA in children who initially had had undetectable
levels in response to antiretroviral therapy. The presence of repeatedly detect-
able RNA suggests the development of resistance or problems with adherence or
drug bioavailability. More frequent evaluation of HIV RNA levels should be con-
sidered if the HIV RNA increase is limited (e.g., if using an HIV RNA assay with a
lower limit of detection of 1,000 copies/mL, there is a ≤0.7 log10 increase from
undetectable to approximately 5,000 copies/mL in an infant aged <2 years). If
adherence to therapy has been inconsistent, renewed efforts to educate the
caregivers and patient and closer follow-up from members of a multidisciplinary
care team may improve adherence.
• A reproducible increase in HIV RNA copy number among children who have had
a substantial HIV RNA response but still have low levels of detectable HIV RNA.
Such an increase would warrant a change in therapy if, after initiation of the
therapeutic regimen, a greater than threefold (>0.5 log10) increase in copy num-
ber is observed in children aged ≥2 years. Because of the greater biologic
variability in RNA in young children, a change in therapy is warranted when a
greater than fivefold (>0.7 log10) increase is observed for children aged <2 years.
Immunologic Considerations for Changing Therapy
CD4+ T-lymphocyte count and percentage are independent predictors of disease
progression and mortality in HIV-infected children (35,36 ). The association of HIV RNA
and CD4+ percentage with long-term mortality risk in HIV-infected children has been
evaluated; for each absolute decline of five percentiles in CD4+ percentage at baseline
or during follow-up, the mortality risk ratio increased by 1.3 (95% CI=1.2–1.5), inde-
pendent of the child’s HIV RNA level (35 ). For children with CD4+ percentages of <15%
(i.e., those in immune category 3), prognosis also was correlated with the degree of
depression of CD4+ percentage (i.e., life expectancy was less for children with CD4+
percentages of <5% compared with children with CD4+ percentages of 10%–14%)
(Table 3).
Before considering changing antiretroviral therapy because of a decline in CD4+
lymphocyte values, a minimum of one repeated measurement of CD4+ values should
be obtained at least 1 week after the initial test. The following are immunologic indica-
tions that may warrant a change in antiretroviral therapy for HIV-infected children:
• Change in immune classification (Table 1). However, minimal changes in CD4+
percentile that may result in a change in immune category (e.g., from 26% to 24%
or from 16% to 14%) may not be as concerning as a rapid substantial change in
CD4+ percentile within the same immune category (e.g., a decrease from 35% to
25%).
• For children with CD4+ percentages of <15% (i.e., those in immune category 3), a
persistent decline of five percentiles or more in CD4+ cell percentage (e.g., from
15% to 10% or from 10% to 5%).
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• A rapid and substantial decrease in absolute CD4+ T-lymphocyte count (e.g., a
>30% decline in <6 months).
Clinical Considerations for Changing Therapy
The occurrence of certain clinical events while receiving antiretroviral therapy
is evidence of HIV disease progression and/or a poor prognosis for infants and chil-
dren. The following clinical criteria warrant consideration of a change in antiretroviral
therapy:
• Progressive neurodevelopmental deterioration (i.e., persistence or progression
of deterioration documented on repeated testing as demonstrated by the pres-
ence of two or more of the following findings: impairment in brain growth,
decline of cognitive function documented by psychometric testing, or clinical
motor dysfunction). In such cases, the new treatment regimen optimally should
include at least one antiretroviral drug with substantial central nervous system
penetration (e.g., ZDV or nevirapine, which have cerebrospinal fluid/plasma
ratios >0.5).
• Growth failure (i.e., persistent decline in weight-growth velocity despite ade-
quate nutritional support and without other explanation).
• Disease progression (i.e., advancement from one pediatric clinical category to
another [Table 2]). Prognosis is poorer as patients progress to more advanced
clinical categories (59 ). However, in patients with stable immunologic and
virologic parameters, progression from one clinical category to another (e.g.,
from clinical category A to category B) may not represent an indication to change
therapy. For example, development of new opportunistic infections, particularly
in patients who had severe immunosuppression at the time therapy was initi-
ated, may not reflect a failure of antiretroviral therapy but persistence of
immunologic dysfunction despite adequate antiviral response. Thus, in patients
whose disease progression is not associated with neurologic deterioration or
growth failure, virologic and immunologic parameters should be considered
when deciding whether to change therapy.
Choice of a New Antiretroviral Regimen
The choice of a new antiretroviral regimen is dictated by the indications that war-
ranted the change in therapy and the limited available alternative antiretroviral
agents. Although the efficacy of different combination antiretroviral regimens in chil-
dren probably can be extrapolated from clinical trial data obtained for adults, data are
limited regarding the pharmacokinetics, appropriate dosing, and short- and long-term
safety of various combinations in infected children. New regimens should be chosen
partly on the basis of the impact of the changes on future treatment options.
The following principles should be followed when choosing a new antiretroviral
regimen in children who have received prior treatment.
• When therapy is changed because of toxicity or intolerance, agents with different
toxicity and side-effect profiles should be chosen, when possible. Health-care
providers should have comprehensive knowledge of the toxicity profile of each
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agent before selecting a new regimen. In the event of drug intolerance, change of
a single drug in a multidrug regimen and, in certain circumstances, dose reduc-
tion are permissible options. However, antiretroviral drugs should only be
reduced to the lower end of the therapeutic range for those antiretrovirals for
which an effective dosing range is known, and adequacy of antiretroviral activity
should be confirmed by the monitoring of HIV RNA levels.
• When changing therapy because of treatment failure (Table 9), adherence to ther-
apy should be assessed as a potential cause of failure.
• If the patient is adherent to the prescribed drug regimen, assume the develop-
ment of drug resistance and, if possible, change at least two drugs to new anti-
retroviral agents. Change in one drug or addition of a drug to a failing regimen is
suboptimal. The new regimen should include at least three drugs, if possible. The
potential for cross-resistance between antiretroviral drugs should be considered
in choosing new drugs.
• When considering changing to a new regimen, all other medications taken by the
patient should be reviewed for possible drug interactions.
• A change to a new regimen, especially one containing protease inhibitors, must
include a discussion of treatment adherence issues between the caregivers of the
infected child and the health-care provider. The health-care provider must recog-
nize that certain medications are difficult to take in combination because of
exacting and often conflicting requirements with respect to whether they can be
taken with food and other antiretrovirals.
• When changing therapy because of disease progression in a patient with ad-
vanced disease, the patient’s quality of life must be considered.
Detailed information regarding issues associated with specific drug choices for
changing a failing regimen and potential cross-resistance between various antiretro-
viral drugs is available elsewhere (5 ). Because these issues are similar for all HIV-
infected persons (regardless of age) they are not addressed specifically in this docu-
ment.
MANAGING ADVERSE DRUG REACTIONS IN THE THERAPY
OF PEDIATRIC HIV INFECTION
The antiretroviral agents used and approved to treat HIV infection in children have
all demonstrated individual and drug-class toxicities that limit the doses and combina-
tions that can be used safely (70 ). The general principles of toxicity management are
similar for adults and children. However, for many of the newer therapies (particularly
the protease inhibitors), limited short-term and no long-term safety data or experience
are available for infants, children, and adolescents. Thus, the amount of information
on which to base guidelines for management of antiretroviral toxicities in children,
especially when antiretroviral drugs are used in combination, is substantially more
limited than that for adults. The data available from PACTG protocol 152 and PACTG
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protocol 300 indicate that some combinations of nucleoside analogues do not sub-
stantially increase the toxicity relative to monotherapy with those agents (54,55 ).
The toxicities of antiretroviral drugs may occur at different frequencies in children
and adults, and the implications of some of the toxicities substantially differ for chil-
dren. The most obvious difference for children from the listing of toxicities in the adult
guidelines is the increased indirect bilirubin associated with indinavir, which is labeled
as inconsequential for adults. This toxicity could be of major consequence for new-
born and young infants because severe hyperbilirubinemia is associated with
kernicterus and would require specific monitoring and treatment should indinavir be
administered to neonates. Additional examples of differences of potential toxicities
between adults and children include the description of asymptomatic retinal depig-
mentation in children associated with ddI therapy and the relative lack of pancreatitis
in children compared with adults receiving ddI therapy (See Appendix).
Another treatment issue that affects children differently from adults concerns the
feasibility of administering poorly palatable liquid antiretroviral formulations to chil-
dren. Innovative techniques to increase palatability may be needed to enable
tolerance of medications (e.g., various methods can be used to increase tolerance of
ritonavir [See Appendix]). Indinavir is associated with hematuria and nephrolithiasis
secondary to crystallization of the drug in the urine; adequate hydration (i.e., 48 oz of
fluid daily) is recommended to reduce the incidence of this side effect. However, en-
suring that voluntary fluid intake of this level is achieved may be more difficult in
children than in adults.
All efforts should be made to continue therapy in the presence of toxicities that are
not life-threatening. Such efforts should include liberal use of adjunctive measures
(e.g., granulocyte colony stimulating factor for treatment of neutropenia and erythro-
poietin and/or transfusions for treatment of anemia). If antiretroviral therapy must be
discontinued for an extended period of time, to minimize the risk for developing drug
resistance, all antiretroviral agents should be stopped simultaneously rather than con-
tinuing one or two agents alone because of potential increased viral replication.
CONCLUSION
The Working Group has attempted to provide information specific to the use of
antiretroviral drugs in infants, children, and adolescents while not duplicating the
information available in antiretroviral recommendations for adults (5 ). Documents
addressing recommendations for adults should be reviewed for basic information
regarding disease pathogenesis and drug interactions. Although the general princi-
ples of therapy are the same for HIV-infected adults, adolescents, children, and infants,
treatment of infection in pediatric patients requires an understanding of the unique
aspects of HIV infection in children. Clinical trials of antiretroviral agents in HIV-
infected children and the development of drug formulations appropriate for admini-
stration to children have often been delayed until after clinical trials in infected adults
have been completed and/or the drug has been approved for use among infected
adults. However, despite these delays, the paucity of pediatric-specific data cannot
further deter the development of rational and reasonable pediatric treatment guide-
lines while studies in children are being undertaken. To maximize therapeutic options
for HIV-infected pediatric patients throughout the course of their infection, drug
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formularies should facilitate the use of all FDA-approved antiretroviral agents as treat-
ment options for children. Additionally, the conduct of clinical trials to define the
pharmacokinetics, safety, and effectiveness in ameliorating the pediatric-specific
manifestations of HIV infection of current and new antiretroviral agents is a priority;
studies of new drugs should be conducted coincident with or soon after initial studies
have been completed in adults. The Working Group will revise these guidelines as
new data regarding antiretroviral therapy for infected infants, children, and adoles-
cents become available.
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Didanosine (dideoxyinosine) (ddI), VIDEX
®
Preparations: Pediatric powder for oral solution (when reconstituted as solution
containing antacid): 10 mg/mL; Chewable tablets with buffers: 25, 50, 100, and 150 mg;
Buffered powder for oral solution: 100, 167, and 250 mg
Dosage
Neonatal dose (infants aged <90 days): 50 mg per m2 of body surface area every
12 hours.
Pediatric usual dose: In combination with other antiretrovirals: 90 mg per m2 of
body surface area every 12 hours.
Pediatric dosage range: 90 to 150 mg per m2 of body surface area every 12 hours.
(Note: may need higher dose in patients with central nervous system disease.)
Adolescent/Adult dose: Body weight ≥60 kg: 200 mg twice daily. Body weight
<60 kg: 125 mg twice daily.
Major toxicities
Most frequent: Diarrhea, abdominal pain, nausea, and vomiting.
Unusual (more severe): Peripheral neuropathy (dose related), electrolyte abnor-
malities, and hyperuricemia.
Uncommon: Pancreatitis (dose related, less common in children than adults),
increased liver enzymes, and retinal depigmentation.
Drug interactions
• Possible decrease in absorption of ketoconazole, itraconazole, and dapsone;
administer at least 2 hours before or 2 hours after ddI.
• Tetracycline and fluoroquinolone antibiotic absorption significantly decreased
(chelation of drug by antacid in pediatric powder and tablets); administer 2 hours
before or 2 hours after ddI.
• Concomitant administration of ddI and delavirdine may decrease the absorption
of these drugs; separate dosing by at least 2 hours.
• Administration with protease inhibitors: indinavir should be administered at least
1 hour before or after ddI on an empty stomach. Ritonavir should be adminis-
tered at least 2 hours before or after ddI.
*Information in this appendix is not all inclusive. Complete and detailed prescribing and toxicity
information on these drugs is available from the drug companies and should be reviewed by
the health-care provider before prescribing these drugs.
†Adolescents in early puberty (Tanner I–II) should be dosed using pediatric schedules, whereas
those in late puberty (Tanner Stage V) should be dosed using adult schedules. Youth who are
in the midst of their growth spurt (Tanner III females and Tanner IV males) should be closely
monitored for medication efficacy and toxicity when choosing adult or pediatric dosing guide-
lines.
Nucleoside Analogue Reverse Transcriptase Inhibitors*
†
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Special instructions
• ddI formulation contains buffering agents or antacids.
• Food decreases absorption; administer ddI on an empty stomach (1 hour before
or 2 hours after a meal). Further evaluation in children regarding administration
with meals is under study.
• For oral solution: shake well and keep refrigerated; admixture is stable for
30 days.
• When administering chewable tablets, at least two tablets should be adminis-
tered to ensure adequate buffering capacity (e.g., if the child’s dose is 50 mg,
administer two 25-mg tablets and not one 50-mg tablet).
Lamivudine (3TC), EPIVIR®
Preparations: Solution: 10 mg/mL; Tablets: 150 mg
Dosage
Neonatal dose (infants aged <30 days): 2 mg per kg of body weight twice daily.
Pediatric dose: 4 mg per kg of body weight twice daily.
Adolescent/Adult dose: Body weight ≥50 kg: 150 mg twice daily. Body weight
<50 kg: 2 mg per kg body weight twice daily.
Major toxicities
Most frequent: Headache, fatigue, nausea, diarrhea, skin rash, and abdominal pain.
Unusual (more severe): Pancreatitis (primarily seen in children with advanced HIV
infection receiving multiple other medications), peripheral neuropathy, decreased
neutrophil count, and increased liver enzymes.
Drug interactions
• Trimethoprim/sulfamethoxazole (TMP/SMX) increases 3TC blood levels (possibly
competes for renal tubular secretion); unknown significance.
• When used with zidovudine (ZDV) may prevent emergence of ZDV resistance,
and for ZDV-resistant virus, revision to phenotypic ZDV sensitivity may be
observed.
Special instructions
• Can be administered with food.
• For oral solution: store at room temperature.
• Decrease dosage in patients with impaired renal function.
Stavudine (d4T), ZERIT
®
Preparations: Solution: 1 mg/mL; Capsules: 15, 20, 30, and 40 mg
Dosage
Neonatal dose: Under evaluation in Pediatric AIDS Clinical Trial Group protocol 332.
Pediatric dose: 1 mg per kg of body weight every 12 hours (up to weight of 30 kg).
Adolescent/Adult dose: Body weight ≥60 kg: 40 mg twice daily. Body weight <60 kg:
30 mg twice daily.
Major toxicities
Most frequent: Headache, gastrointestinal disturbances, and skin rashes.
Uncommon (more severe): Peripheral neuropathy and pancreatitis.
Other: Increased liver enzymes.
Drug interactions
• Drugs that decrease renal function could decrease clearance.
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• Should not be administered in combination with zidovudine (poor antiretroviral
effect).
Special instructions
• Can be administered with food.
• Need to decrease dose in patients with renal impairment.
• For oral solution: shake well and keep refrigerated; solution stable for 30 days.
Zalcitabine (ddC), HIVID
®
Preparations: Syrup: 0.1 mg/mL (investigational); Tablets: 0.375 and 0.75 mg
Dosage
Neonatal dose: Unknown.
Pediatric usual dose: 0.01 mg per kg of body weight every 8 hours.
Pediatric dosage range: 0.005 to 0.01 mg per kg of body weight every 8 hours.
Adolescent/Adult dose: 0.75 mg three times a day.
Major toxicities
Most frequent: Headache, gastrointestinal disturbances, and malaise.
Unusual (more severe): Peripheral neuropathy, pancreatitis, hepatic toxicity, oral
ulcers, esophageal ulcers, hematologic toxicity, and skin rashes.
Drug interactions
• Cimetidine, amphotericin, foscarnet, and aminoglycosides may decrease renal
clearance of ddC.
• Antacids decrease absorption of ddC.
• Concomitant use with ddI is not recommended because of the increased risk of
peripheral neuropathy.
• Intravenous pentamidine increases the risk for pancreatitis; do not use concur-
rently.
Special instructions
• Administer on an empty stomach (1 hour before or 2 hours after a meal).
• Decrease dosage in patients with impaired renal function.
Zidovudine (ZDV, AZT), RETROVIR
®
Preparations: Syrup: 10 mg/mL; Capsules: 100 mg; Tablets: 300 mg; Concentrate for
injection/for intravenous infusion: 10 mg/mL
Dosage
Dose for premature infants: (Standard neonatal dose may be excessive in pre-
mature infants.) Under study in Pediatric AIDS Clinical Trial Group protocol 331:
1.5 mg per kg of body weight every 12 hours from birth to 2 weeks of age; then in-
crease to 2 mg per kg of body weight every 8 hours after 2 weeks of age.
Neonatal dose: Oral: 2 mg per kg of body weight every 6 hours. Intravenous: 1.5 mg
per kg of body weight every 6 hours.
Pediatric usual dose: Oral: 160 mg per m2 of body surface area every 8 hours. Intra-
venous (intermittent infusion): 120 mg per m2 of body surface area every 6 hours.
Intravenous (continuous infusion): 20 mg per m2 of body surface area per hour.
Pediatric dosage range: 90 mg per m2 of body surface area to 180 mg per m2 of
body surface area every 6–8 hours.
Adolescent/Adult dose: 200 mg three times a day or 300 mg twice daily.
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Major toxicities
Most frequent: Hematologic toxicity, including granulocytopenia and anemia, and
headache.
Unusual: Myopathy, myositis, and liver toxicity.
Drug interactions
• Increased toxicity may be observed with concomitant administration of the fol-
lowing drugs (therefore, more intensive toxicity monitoring may be warranted):
ganciclovir, interferon-alpha, TMP/SMX, acyclovir, and other drugs that can be
associated with bone marrow suppression.
• The following drugs may increase ZDV concentration (and therefore potential
toxicity): probenecid, atovaquone, methadone, valproic acid, and fluconazole.
• Decreased renal clearance may be observed with co-administration of cimetidine
(may be significant in patients with renal impairment).
• ZDV metabolism may be increased with co-administration of rifampin and
rifabutin (clinical significance unknown); clarithromycin may decrease concen-
trations of ZDV probably by interfering with absorption (preferably administer
4 hours apart).
• Ribavirin decreases the intracellular phosphorylation of ZDV (conversion to
active metabolite).
• Phenytoin concentrations may increase or decrease.
• Should not be administered in combination with d4T (poor antiretroviral effect).
Special instructions
• Can be administered with food (although the manufacturer recommends
administration 30 minutes before or 1 hour after a meal).
• Decrease dosage in patients with severe renal impairment.
• Substantial granulocytopenia or anemia may necessitate interruption of therapy
until marrow recovery is observed; use of erythropoietin, filgrastim, or reduced
ZDV dosage may be necessary in some patients.
• Reduced dosage may be indicated in patients with substantial hepatic dysfunc-
tion.
• Infuse intravenous loading dose or intermittent infusion dose over 1 hour.
• For intravenous solution: dilute with 5% dextrose injection solution to concentra-
tion ≤4 mg/mL; refrigerated diluted solution is stable for 24 hours.
• Some experts in pediatric HIV infection use a dose of 180 mg per m2 of body
surface area every 12 hours when using in drug combinations with other anti-
retroviral compounds, but data on this dosing in children is limited.
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*Information in this appendix is not all inclusive. Complete and detailed prescribing and toxicity
information on these drugs is available from the drug companies and should be reviewed by
the health-care provider before prescribing these drugs.
†Adolescents in early puberty (Tanner I–II) should be dosed using pediatric schedules, whereas
those in late puberty (Tanner Stage V) should be dosed using adult schedules. Youth who are
in the midst of their growth spurt (Tanner III females and Tanner IV males) should be closely
monitored for medication efficacy and toxicity when choosing adult or pediatric dosing guide-
lines.
§Drugs metabolized by the hepatic cytochrome P450 enzyme system have the potential for
significant interactions with multiple drugs, some of which may be life-threatening. These
interactions are outlined in detail in prescribing information available from the drug companies.
These interactions will not be reiterated in this document, and the health-care provider should
review those documents for detailed information. Before therapy with these drugs is initiated,
the patient’s medication profile should be carefully reviewed for potential drug interactions.
Delavirdine (DLV), RESCRIPTOR®




Adolescent/Adult dose: 400 mg three times a day.
Major toxicities
Most frequent: Headache, fatigue, gastrointestinal complaints, and rash (may be
severe).
Drug interactions
• Metabolized in part by hepatic cytochrome P450 3A (CYP3A). There could poten-
tially be multiple drug interactions.
§
• Before administration, the patient’s medication profile should be carefully re-
viewed for potential drug interactions.
• DLV decreases the metabolism of certain drugs, resulting in increased drug levels
and potential toxicity. DLV is not recommended for concurrent use with antihista-
mines (e.g., astemizole or terfenadine); sedative-hypnotics (e.g., alprazolam,
midazolam, or triazolam); calcium channel blockers (e.g., nifedipine); ergot alka-
loid derivatives; amphetamines; cisapride; or warfarin.
• DLV clearance is increased, resulting in substantially reduced concentrations of
DLV, with concurrent use of rifabutin, rifampin, or anticonvulsants (e.g., pheny-
toin, carbamazepine, or phenobarbital). Concurrent use is not recommended.
• Absorption of DLV is decreased if given with antacids or histamine2 receptor
antagonists.
• Increased trough concentrations of DLV if given with ketoconazole or fluoxetine;
increased levels of both drugs if DLV is given with clarithromycin.
• DLV increases levels of dapsone and quinidine.
• Administration with protease inhibitors: decreases metabolism of saquinavir and
indinavir, resulting in a significant increase in saquinavir and indinavir concentra-
tions and a slight decrease in DLV concentrations.
Special instructions
• Can be administered with food.
• Should be taken 1 hour before or 1 hour after ddI or antacids.
• Tablets can be dissolved in water and the resulting dispersion taken promptly.
Non-nucleoside Reverse Transcriptase Inhibitors*
†
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*Drugs metabolized by the hepatic cytochrome P450 enzyme system have the potential for
significant interactions with multiple drugs, some of which may be life-threatening. These
interactions are outlined in detail in prescribing information available from the drug companies.
These interactions will not be reiterated in this document, and the health-care provider should
review those documents for detailed information. Before therapy with these drugs is initiated,
the patient’s medication profile should be carefully reviewed for potential drug interactions.
Nevirapine (NVP), VIRAMUNE
®
Preparations: Suspension: 10 mg/mL (investigational); Tablets: 200 mg
Dosage
Neonatal dose (through age 3 months): Under study in Pediatric AIDS Clinical Trial
Group protocol 356: 5 mg per kg of body weight once daily for 14 days, followed by
120 mg per m2 of body surface area every 12 hours for 14 days, followed by 200 mg
per m2 of body surface area every 12 hours.
Pediatric dose: 120 to 200 mg per m2 of body surface area every 12 hours. Note:
Initiate therapy with 120 mg per m2 of body surface area administered once daily for
14 days. Increase to full dose administered every 12 hours if there are no rash or other
untoward effects.
Adolescent/Adult dose: 200 mg every 12 hours. Note: Initiate therapy at half dose
for the first 14 days. Increase to full dose if there is no rash or other untoward effects.
Major toxicities
Most frequent: Skin rash (some severe and life-threatening, including Stevens-
Johnson syndrome), sedative effect, headache, diarrhea, and nausea.
Unusual: Elevated liver enzymes and, rarely, hepatitis.
Drug interactions
• Induces hepatic cytochrome P450 3A (CYP3A); autoinduction of metabolism oc-
curs in 2–4 weeks with a 1.5-fold to twofold increase in clearance. There could
potentially be multiple drug interactions.*
• Before administration, the patient’s medication profile should be carefully re-
viewed for potential drug interactions.
• Drugs having suspected interactions and should be used only with careful moni-
toring: rifampin and rifabutin; oral contraceptives (alternative or additional
methods of birth control should be used if co-administering with hormonal meth-
ods of birth control); sedative-hypnotics (e.g., triazolam or midazolam); oral
anticoagulants; digoxin; phenytoin; or theophylline.
• Administration with protease inhibitors: indinavir and saquinavir concentrations
are decreased significantly, and ritonavir concentration may be decreased.
Whether increased doses of protease inhibitors are needed is unknown.
Special instructions
• Can be administered with food.
• May be administered concurrently with ddI.
• NVP-associated skin rash usually occurs within the first 6 weeks of therapy. If
rash occurs during the initial 14-day lead-in period, do not increase dose until
rash resolves. NVP should be discontinued immediately in patients who develop
severe rash or a rash accompanied by constitutional symptoms (i.e., fever, oral
lesions, conjunctivitis, or blistering).
• For investigational suspension: Must be shaken well; store at room temperature.
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*Information in this appendix is not all inclusive. Complete and detailed prescribing and toxicity
information on these drugs is available from the drug companies and should be reviewed by
the health-care provider before prescribing these drugs.
†Adolescents in early puberty (Tanner I–II) should be dosed using pediatric schedules, whereas
those in late puberty (Tanner Stage V) should be dosed using adult schedules. Youth who are
in the midst of their growth spurt (Tanner III females and Tanner IV males) should be closely
monitored for medication efficacy and toxicity when choosing adult or pediatric dosing guide-
lines.
§Data in children is limited, and doses may change as more information is obtained about the
pharmacokinetics of these drugs in children.
¶Drugs metabolized by the hepatic cytochrome P450 enzyme system have the potential for
significant interactions with multiple drugs, some of which may be life-threatening. These
interactions are outlined in detail in prescribing information available from the drug companies.
These interactions will not be reiterated in this document, and the health-care provider should
review those documents for detailed information. Before therapy with these drugs is initiated,
the patient’s medication profile should be carefully reviewed for potential drug interactions.
Indinavir, CRIXIVAN
®
Preparations: Capsules: 200 and 400 mg
Dosage
Neonatal Dose: Unknown. Due to side effect of hyperbilirubinemia, should not be
given to neonates until further information is available.
Pediatric Dose: Under study in clinical trials: 500 mg per m2 of body surface area
every 8 hours.
Adolescent/Adult dose: 800 mg every 8 hours.
Major toxicities
Most frequent: Nausea, abdominal pain, headache, metallic taste, dizziness, and
asymptomatic hyperbilirubinemia (10%).
Unusual (more severe): Nephrolithiasis (4%) and exacerbation of chronic liver
disease.
Rare: Spontaneous bleeding episodes in hemophiliacs, hyperglycemia, keto-
acidosis, diabetes, and hemolytic anemia.
Drug interactions
• Cytochrome P450 3A4 (CYP3A4) responsible for metabolism. There could poten-
tially be multiple drug interactions.
¶
• Before administration, the patient’s medication profile should be carefully re-
viewed for potential drug interactions.
• Indinavir decreases the metabolism of certain drugs, resulting in increased drug
levels and potential toxicity. Indinavir is not recommended for concurrent use
with antihistamines (e.g., astemizole or terfenadine); cisapride; ergot alkaloid de-
rivatives; or sedative-hypnotics (e.g., triazolam or midazolam).
• Indinavir levels are significantly reduced with concurrent use of rifampin. Con-
current use is not recommended.
• Rifabutin concentrations are increased, therefore a dose reduction of rifabutin to
half the usual daily dose is recommended. 
• Ketoconazole and itraconazole cause an increase in indinavir concentrations
(consider reducing adolescent/adult indinavir dose to 600 mg every 8 hours). 
• Co-administration of clarithromycin increases serum concentration of both drugs
(dosing modification not needed).
• Co-administration of nevirapine may decrease indinavir serum concentration.
Protease Inhibitors*
†§
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*Drugs metabolized by the hepatic cytochrome P450 enzyme system have the potential for
significant interactions with multiple drugs, some of which may be life-threatening. These
interactions are outlined in detail in prescribing information available from the drug companies.
These interactions will not be reiterated in this document, and the health-care provider should
review those documents for detailed information. Before therapy with these drugs is initiated,
the patient’s medication profile should be carefully reviewed for potential drug interactions.
• Administration with other protease inhibitors: co-administration with nelfinavir
increases concentration of both drugs; co-administration with saquinavir
increases concentration of saquinavir.
Special instructions
• Administer on an empty stomach 1 hour before or 2 hours after a meal (or can
take with a light meal).
• Adequate hydration required to minimize risk of nephrolithiasis (at least 48 oz of
fluid daily in adult patients).
• If co-administered with ddI, give at least 1 hour apart on an empty stomach.
• Decrease dose in patients with hepatic insufficiency.




Preparations: Powder for oral suspension: 50 mg per 1 level gram scoopful (200 mg
per 1 level teaspoon); Tablets: 250 mg tablet
Dosage
Neonatal dose: Under study in Pediatric AIDS Clinical Trial Group protocol 353:
10 mg per kg of body weight three times a day. (Note: no preliminary data available,
investigational.)
Pediatric dose: 20 to 30 mg per kg of body weight three times a day.
Adolescent/Adult dose: 750 mg three times a day.
Major toxicities
Most frequent: Diarrhea.
Less common: Asthenia, abdominal pain, rash, and exacerbation of chronic liver
disease.
Rare: Spontaneous bleeding episodes in hemophiliacs, hyperglycemia, keto-
acidosis, and diabetes.
Drug interactions
• Nelfinavir is in part metabolized by cytochrome P450 3A4 (CYP3A4). There could
potentially be multiple drug interactions.*
• Before administration, the patient’s medication profile should be carefully re-
viewed for potential drug interactions. 
• Nelfinavir decreases the metabolism of certain drugs, resulting in increased drug
levels and potential toxicity. Nelfinavir is not recommended for concurrent use
with antihistamines (e.g., astemizole or terfenadine); cisapride; ergot alkaloid
derivatives; certain cardiac drugs (e.g., quinidine or amiodarone); or sedative-
hypnotics (e.g., triazolam or midazolam).
• Nelfinavir levels are greatly reduced with concurrent use of rifampin. Concurrent
use is not recommended.
• Rifabutin causes less decline in nelfinavir concentrations; if co-administered with
nelfinavir, rifabutin should be reduced to one half the usual dose.
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• Estradiol levels are reduced by nelfinavir, and alternative or additional methods
of birth control should be used if co-administering with hormonal methods of
birth control.
• Co-administration with delavirdine (DLV) increases nelfinavir concentrations
twofold and decreases DLV concentrations by 50%. There are no data on co-
administration with nevirapine, but some experts use higher doses of nelfinavir
if used in combination with nevirapine.
• Administration with other protease inhibitors: co-administration with indinavir
increases concentration of both drugs; co-administration with saquinavir in-
creases concentration of saquinavir with little change in nelfinavir concentration;
co-administration with ritonavir increases concentration of nelfinavir without
change in ritonavir concentration.
Special instructions
• Administer with meal or light snack.
• If co-administered with ddI, nelfinavir should be administered 2 hours before or
1 hour after ddI.
• For oral solution: powder may be mixed with water, milk, pudding, ice cream, or
formula (for up to 6 hours). 
• Do not mix with any acidic food or juice because of resulting poor taste.
• Do not add water to bottles of oral powder; a special scoop is provided with oral
powder for measuring purposes.
• Tablets readily dissolve in water and produce a dispersion that can be mixed with




Preparations: Oral solution: 80 mg/mL; Capsules: 100 mg
Dosage
Neonatal dose: Under study in Pediatric AIDS Clinical Trial Group protocol 354 (sin-
gle dose pharmacokinetics).
Pediatric usual dose: 400 mg per m2 of body surface area every 12 hours. To mini-
mize nausea/vomiting, initiate therapy starting at 250 mg per m2 of body surface area
every 12 hours and increase stepwise to full dose over 5 days as tolerated.
Pediatric dosage range: 350 to 400 mg per m2 of body surface area every 12 hours.
Adolescent/Adult dose: 600 mg twice daily. To minimize nausea/vomiting, initiate
therapy starting at 300 mg twice daily and increase stepwise to full dose over 5 days
as tolerated.
Major toxicities
Most frequent: Nausea, vomiting, diarrhea, headache, abdominal pain, and
anorexia.
Less common: Circumoral paresthesias and increase in liver enzymes.
Rare: Spontaneous bleeding episodes in hemophiliacs, pancreatitis, increased
levels of triglycerides and cholesterol, hyperglycemia, ketoacidosis, diabetes, and
hepatitis.
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*Drugs metabolized by the hepatic cytochrome P450 enzyme system have the potential for
significant interactions with multiple drugs, some of which may be life-threatening. These
interactions are outlined in detail in prescribing information available from the drug companies.
These interactions will not be reiterated in this document, and the health-care provider should
review those documents for detailed information. Before therapy with these drugs is initiated,
the patient’s medication profile should be carefully reviewed for potential drug interactions.
Drug interactions
• Ritonavir is extensively metabolized by hepatic cytochrome P450 3A (CYP3A).
There could potentially be multiple drug interactions.*
• Before administration, the patient’s medication profile should be carefully
reviewed for potential drug interactions.
• Not recommended for concurrent use with analgesics (e.g., meperidine, piroxi-
cam, or propoxyphene); antihistamines (e.g., astemizole or terfenadine); certain
cardiac drugs (e.g., amiodarone, bepridil hydrochloride, encainide hydrochlo-
ride, flecainide acetate, propafenone, or quinidine); ergot alkaloid derivatives;
cisapride; sedative-hypnotics (e.g., alprazolam, clorazepate, diazepam, estazo-
lam, flurazepam hydrochloride, midazolam, triazolam, or zolpidem tartrate);
certain psychotropic drugs (e.g., bupropion hydrochloride, clozapine, or pimoz-
ide); rifampin; or rifabutin.
• Estradiol levels are reduced by ritonavir, and alternative or additional methods of
birth control should be used if co-administering with hormonal methods of birth
control.
• Ritonavir increases metabolism of theophylline (levels should be monitored, and
dose may need to be increased).
• Ritonavir increases levels of clarithromycin (dose adjustment may be necessary
in patients with impaired renal function); desipramine (dose adjustment may be
necessary); and warfarin (monitoring of anticoagulant effect is necessary).
• Ritonavir may increase or decrease digoxin levels (monitoring of levels is recom-
mended).
• Drugs that increase CYP3A activity can lead to increased clearance and therefore
lower levels of ritonavir include carbamazepine, dexamethasone, phenobarbital,
and phenytoin (anticonvulsant levels should be monitored because ritonavir can
affect the metabolism of these drugs as well).
• Administration with other protease inhibitors: co-administration with saquinavir
and nelfinavir increases concentration of these drugs with little change in rito-
navir concentration.
Special instructions
• Administration with food increases absorption.
• If ritonavir is prescribed with ddI, there should be 2 hours between taking each of
the drugs.
• Oral solution must be kept refrigerated and stored in original container; can be
kept at room temperature if used within 30 days.
• To minimize nausea, therapy should be initiated at a low dose and increased to
full dose over 5 days as tolerated.
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* Drugs metabolized by the hepatic cytochrome P450 enzyme system have the potential for
significant interactions with multiple drugs, some of which may be life-threatening. These
interactions are outlined in detail in prescribing information available from the drug companies.
These interactions will not be reiterated in this document, and the health-care provider should
review those documents for detailed information. Before therapy with these drugs is initiated,
the patient’s medication profile should be carefully reviewed for potential drug interactions.
• Techniques to increase tolerance in children: a) mixing oral solution with milk,
chocolate milk, or vanilla or chocolate pudding or ice cream; b) dulling the taste
buds before administration by chewing ice, giving popsicles or spoonfuls of par-
tially frozen orange or grape juice concentrates; c) coating the mouth by giving
peanut butter to eat before the dose; or d) administration of strong-tasting foods
such as maple syrup, cheese, or strong-flavored chewing gum immediately after
dose.
Saquinavir, INVIRASE  (hard gel capsule) and FORTOVASE (soft gel
capsule)
Preparations: Hard gel capsules: 200 mg; Soft gel capsules: 200 mg
Dosage
Neonatal dose: Unknown.
Pediatric dose: Unknown (will be studied in Pediatric AIDS Clinical Trials Group pro-
tocol 397).
Adolescent/Adult dose: Hard gel capsules: 600 mg three times a day; Soft gel cap-
sules: 1200 mg three times a day.
Major toxicities
Most frequent: Diarrhea, abdominal discomfort, headache, nausea, paresthesias,
and skin rash.
Less common: Exacerbation of chronic liver disease.
Rare: Spontaneous bleeding episodes in hemophiliacs, hyperglycemia, keto-
acidosis, and diabetes.
Drug interactions
• Saquinavir is metabolized by the cytochrome P450 3A4 (CYP 3A4) system in the
liver, and there are numerous potential drug interactions.*
• Before administration, the patient’s medication profile should be carefully re-
viewed for potential drug interactions.
• Saquinavir decreases the metabolism of certain drugs, resulting in increased
drug levels and potential toxicity. Saquinavir is not recommended for concurrent
use with antihistamines (e.g., astemizole or terfenadine); cisapride; ergot alkaloid
derivatives, or sedative-hypnotics (e.g., midazolam or triazolam).
• Saquinavir levels are significantly reduced with concurrent use of rifampin (de-
creases saquinavir levels by 80%), rifabutin (decreases saquinavir levels by 40%),
and nevirapine (decreases saquinavir levels by 25%).
• Saquinavir levels are decreased by carbamazepine, dexamethasone, pheno-
barbital, and phenytoin.
• Saquinavir levels are increased by delvirdine and ketoconazole.
• Saquinavir may increase levels of calcium channel blockers, clindamycin, dap-
sone, and quinidine. If used concurrently, patients should be closely monitored
for toxicity.
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• Administration with other protease inhibitors: co-administration with indinavir,
ritonavir, or nelfinavir increases concentration of saquinavir with little change in
concentration of the other drug.
Special instructions
• Administer within 2 hours of a full meal to increase absorption.
• Concurrent administration of grapefruit juice increases saquinavir concentration.
• Sun exposure can cause photosensitivity reactions, therefore sunscreen or pro-
tective clothing is recommended.
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